- About us
- Clinical trials
- News & Publications
SOTIO is developing SO-N106 as an ADC against an undisclosed target.
SO-N106 has demonstrated potent anti-tumor efficacy in vitro and in vivo and, due to NBE’s proprietary site-specific sortase mediated antibody coupling (SMAC) conjugation platform, has superior manufacturing properties including stability and aggregation propensity.